BRPI0315959B8 - composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto - Google Patents

composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto

Info

Publication number
BRPI0315959B8
BRPI0315959B8 BRPI0315959A BR0315959A BRPI0315959B8 BR PI0315959 B8 BRPI0315959 B8 BR PI0315959B8 BR PI0315959 A BRPI0315959 A BR PI0315959A BR 0315959 A BR0315959 A BR 0315959A BR PI0315959 B8 BRPI0315959 B8 BR PI0315959B8
Authority
BR
Brazil
Prior art keywords
compound
overweight
treatment
pharmaceutical composition
mortality associated
Prior art date
Application number
BRPI0315959A
Other languages
English (en)
Other versions
BR0315959A (pt
BRPI0315959C1 (pt
BRPI0315959B1 (pt
Inventor
Sastri Kambhampati Rama
Satya Nirogi Ramakrishna Venkata
Satya Veerabhadra Vadlamudi Rao Venkata
Jasti Venkateswarlu
Shreekrishna Shirsath Vikas
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of BR0315959A publication Critical patent/BR0315959A/pt
Publication of BRPI0315959B1 publication Critical patent/BRPI0315959B1/pt
Publication of BRPI0315959B8 publication Critical patent/BRPI0315959B8/pt
Publication of BRPI0315959C1 publication Critical patent/BRPI0315959C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto". a presente invenção refere-se a novos compostos de narilasulfonila-3- indolo substituído, seus derivados, seus análogos, suas formas tautoméricas, seus estereoisômeros, suas formas geométricas, seus n-óxidos, seus polimorfos, seus sais farmaceuticamente aceitáveis, seus solvatos farmaceuticamente aceitáveis e às composições farmaceuticamente aceitáveis contendo os mesmos. a presente invenção refere-se particularmente aos novos n-arilasulfonila-3-indolos substituídos tendo a fórmula (i) , seus derivados, seus análogos, suas formas tautoméricas, seus estereoisômeros, suas formas geométricas, seus óxidos de n, seus polimorfos, seus sais farmaceuticamente aceitáveis, seus solvatos farmaceuticamente aceitáveis e às composições farmaceuticamente aceitáveis contendo os mesmos. a presente invenção também refere-se ao processo para a preparação dos compostos da fórmula (i), as composições farmacêuticas que contém tais compostos e ao uso de tais compostos e composições na medicina. esta invenção também está relacionada aos intermediários inovadores envolvidos nos mesmos e ao processo para a sua preparação.
BRPI0315959A 2002-11-28 2003-06-05 composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto BRPI0315959C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN884/MAS/2002 2002-11-28
IN884MA2002 2002-11-28
PCT/IN2003/000209 WO2004048330A1 (en) 2002-11-28 2003-06-05 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them

Publications (4)

Publication Number Publication Date
BR0315959A BR0315959A (pt) 2005-09-13
BRPI0315959B1 BRPI0315959B1 (pt) 2017-12-19
BRPI0315959B8 true BRPI0315959B8 (pt) 2018-01-16
BRPI0315959C1 BRPI0315959C1 (pt) 2021-05-25

Family

ID=40184827

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0315959A BRPI0315959C1 (pt) 2002-11-28 2003-06-05 composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto
BRPI0318799A BRPI0318799B8 (pt) 2002-11-28 2003-06-05 processo para a preparação de um composto

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0318799A BRPI0318799B8 (pt) 2002-11-28 2003-06-05 processo para a preparação de um composto

Country Status (21)

Country Link
US (1) US7875605B2 (pt)
EP (1) EP1581492B1 (pt)
JP (1) JP4559230B2 (pt)
KR (1) KR100818508B1 (pt)
CN (2) CN1720225B (pt)
AT (1) ATE401307T1 (pt)
AU (1) AU2003237599B2 (pt)
BR (2) BRPI0315959C1 (pt)
CA (1) CA2509982C (pt)
CY (1) CY1108786T1 (pt)
DE (1) DE60322266D1 (pt)
DK (1) DK1581492T3 (pt)
EA (1) EA011320B1 (pt)
ES (1) ES2310243T3 (pt)
MX (1) MXPA05005701A (pt)
NO (2) NO330341B1 (pt)
NZ (2) NZ540840A (pt)
PT (1) PT1581492E (pt)
SI (1) SI1581492T1 (pt)
WO (1) WO2004048330A1 (pt)
ZA (1) ZA200504043B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1476151B1 (en) * 2002-02-12 2008-07-16 N.V. Organon 1-arylsulfonyl-3-substitued indole and indoline derivates useful in the treatment of central nervous system disorders
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
PL1704154T3 (pl) 2004-01-02 2009-10-30 Suven Life Sciences Ltd Nowe indeno[2,1a]indeny i izoindolo[2,1-a]indole
MX2008001292A (es) 2005-07-29 2008-03-25 Hoffmann La Roche Nuevos derivados de indol-3-il-carbonil-piperidina y piperazina.
WO2007020653A1 (en) * 2005-08-12 2007-02-22 Suven Life Sciences Limited Thioether derivatives as functional 5-ht6 ligands
PT1919896E (pt) 2005-08-12 2010-02-26 Suven Life Sciences Ltd Derivados de aminoaril sulfonamida como ligandos funcionais de 5-ht6
WO2007020654A1 (en) 2005-08-16 2007-02-22 Suven Life Sciences An improved process for the preparation of losartan
CN101563321B (zh) * 2007-01-08 2012-05-30 苏文生命科学有限公司 4-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途
MX2009006077A (es) * 2007-01-08 2009-06-17 Suven Life Sciences Ltd Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6.
KR101162482B1 (ko) 2007-05-03 2012-07-03 수벤 라이프 사이언시스 리미티드 아미노알콕시 아릴술폰아미드 화합물 및 ５-ｈｔ６ 리간드로서의 그의 용도
US7807705B2 (en) * 2007-05-18 2010-10-05 The Ohio State University Research Foundation Potent indole-3-carbinol-derived antitumor agents
DK2200980T3 (da) 2007-10-26 2011-11-21 Suven Life Sciences Ltd Aminoarylsulfonamidforbindelser og deres anvendelse som 5-HT6-ligander
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
HRP20130721T1 (en) 2008-09-17 2013-09-30 Suven Life Sciences Limited Aryl sulfonamide amine compounds and their use as 5-ht6 ligands
US8912220B2 (en) * 2009-08-10 2014-12-16 Galenea Pharmaceuticals Compounds and methods of use thereof
US8153680B2 (en) * 2009-08-25 2012-04-10 The Ohio State University Research Foundation Alkyl indole-3-carbinol-derived antitumor agents
AU2010340745B2 (en) 2010-01-05 2014-11-20 Suven Life Sciences Limited Sulfone compounds as 5-HT6 receptor ligands
CN102093149A (zh) * 2010-12-08 2011-06-15 天津理工大学 一种促进氰基快速水解制备羧酸类化合物的方法
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
KR101534136B1 (ko) * 2013-06-11 2015-07-07 이화여자대학교 산학협력단 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 5-ht6 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
AU2014358682B2 (en) 2013-12-02 2016-10-20 Suven Life Sciences Limited Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
DK3180001T3 (en) * 2014-08-16 2019-04-01 Suven Life Sciences Ltd ACTIVE METABOLITE OF 1 - [(2-BROMPHENYL) SULPHONYL] -5-METHOXY-3 - [(4-METHYL-1-PIPERAZINYL) METHYL] -1H-INDOL-DIMESYLATE-MONOHYDRATE AND DIMESYLATE-DIHYDRATE SALT
NZ748280A (en) * 2016-05-18 2020-07-31 Suven Life Sciences Ltd Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors
SG11201809725TA (en) * 2016-05-18 2018-12-28 Suven Life Sciences Ltd Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
KR102016120B1 (ko) 2016-05-18 2019-10-21 수벤 라이프 사이언시스 리미티드 순수한 5-ht6 수용체 길항제, 아세틸콜린에스테라제 저해제 및 nmda 수용체 길항제의 3중 조합물
RS62113B1 (sr) * 2016-10-03 2021-08-31 Suven Life Sciences Ltd Farmaceutske kompozicije antagoniste 5-ht6
CN107174586B (zh) * 2017-02-21 2020-08-11 中国科学院昆明植物研究所 以芦竹碱衍生物为活性成分的药物组合物及其应用
IL271694B2 (en) * 2017-07-03 2025-01-01 Suven Life Sciences Ltd New uses of a pure 5-HT6 receptor antagonist – the compound 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1-hydrogen-indole or its pharmaceutically acceptable salts
US20220409614A1 (en) 2019-12-02 2022-12-29 Suven Life Sciences Limited Treating behavioral and psychological symptoms in dementia patients
MA57828B1 (fr) 2019-12-02 2025-09-30 Suven Life Sciences Limited Combinaisons du masupirdine avec du donépézil ou de la mémantine pour le traitement de symptômes comportementaux et psychologiques chez des patients atteints de démence
CN111362858B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
CN111233737B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
KR102347372B1 (ko) 2020-12-14 2022-01-07 (주)케이메디켐 신규한 인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물
CN115504925B (zh) * 2021-06-22 2024-03-12 广东药科大学 一类ppar激动剂、其制备方法及其作为药物的用途
CN117534656A (zh) * 2023-11-17 2024-02-09 寿光富康制药有限公司 一种富马酸伏诺拉生的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1305458A (pt) 1969-02-26 1973-01-31
ZA795239B (en) 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
JPH04208263A (ja) * 1990-01-02 1992-07-29 Fujisawa Pharmaceut Co Ltd インドール誘導体およびそれらの製造法
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
KR100215627B1 (ko) 1990-06-07 1999-08-16 레슬리 제인 에드워즈 치료용 헤테로사이클 화합물
SK278998B6 (sk) 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
TW263508B (pt) * 1991-02-12 1995-11-21 Pfizer
GB9113802D0 (en) 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
JP3223193B2 (ja) 1991-08-09 2001-10-29 株式会社日清製粉グループ本社 インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質
GB9210400D0 (en) 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
KR940007001A (ko) 1992-09-16 1994-04-26 최승주 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
ES2291024T4 (es) * 1999-04-21 2009-03-01 Nps Allelix Corp. Compuestos de piperidina-indol con afinidad con 5-ht6.
JP2000344744A (ja) * 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
CN1317276C (zh) 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
AU9619301A (en) * 2000-10-20 2002-04-29 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
WO2002041889A2 (en) * 2000-11-24 2002-05-30 Smithkline Beecham P.L.C. Indolsulfonyl compounds useful in the treatment of cns disorders
EP1351688A4 (en) * 2000-12-11 2006-01-04 Smithkline Beecham Corp UROTENSIN-II RECEPTOR ANTAGONISTS
MXPA03005433A (es) * 2000-12-22 2003-09-10 Wyeth Corp Compuestos de heterociclilalquilindol o-azaindol como ligandos de 5-hidroxitriptamina-6.
EP1359915A4 (en) * 2001-01-26 2004-07-21 Smithkline Beecham UROTENSIN-II RECEPTOR ANTAGONISTS
EP1476151B1 (en) * 2002-02-12 2008-07-16 N.V. Organon 1-arylsulfonyl-3-substitued indole and indoline derivates useful in the treatment of central nervous system disorders

Also Published As

Publication number Publication date
BR0315959A (pt) 2005-09-13
SI1581492T1 (sl) 2008-12-31
JP4559230B2 (ja) 2010-10-06
ZA200504043B (en) 2006-07-26
US7875605B2 (en) 2011-01-25
CN1720225B (zh) 2011-05-18
KR20050086868A (ko) 2005-08-30
NO330341B1 (no) 2011-03-28
NO20052737L (no) 2005-08-25
NO20085054L (no) 2005-08-25
BRPI0315959C1 (pt) 2021-05-25
CN101544592A (zh) 2009-09-30
HK1133002A1 (en) 2010-03-12
NZ540840A (en) 2008-12-24
JP2006514011A (ja) 2006-04-27
MXPA05005701A (es) 2005-08-16
ATE401307T1 (de) 2008-08-15
CA2509982C (en) 2011-11-08
DK1581492T3 (da) 2008-11-10
US20060223890A1 (en) 2006-10-05
DE60322266D1 (de) 2008-08-28
BRPI0318799B1 (pt) 2019-06-25
ES2310243T3 (es) 2009-01-01
EP1581492B1 (en) 2008-07-16
BRPI0318799B8 (pt) 2021-05-25
NZ572186A (en) 2010-02-26
HK1083217A1 (en) 2006-06-30
WO2004048330A8 (en) 2005-10-27
CY1108786T1 (el) 2014-04-09
NO335015B1 (no) 2014-08-25
CN101544592B (zh) 2013-08-21
BRPI0315959B1 (pt) 2017-12-19
NO20052737D0 (no) 2005-06-08
KR100818508B1 (ko) 2008-03-31
AU2003237599B2 (en) 2009-06-18
WO2004048330A1 (en) 2004-06-10
CA2509982A1 (en) 2004-06-10
PT1581492E (pt) 2008-09-19
EP1581492A1 (en) 2005-10-05
EA200500881A1 (ru) 2005-12-29
CN1720225A (zh) 2006-01-11
EA011320B1 (ru) 2009-02-27
AU2003237599A1 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
BR0315959A (pt) Composto, composição farmacêutica uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto
CY1111876T1 (el) Νεες πυρρολες με υπολiπiδaiμiκες και υποχοληστερολαιμικες δραστικοτητες, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τις περιεχουν και η χρηση αυτων στην ιατρικη
EA200600925A1 (ru) Производные триазола в качестве антагонистов вазопрессина
CY1114417T1 (el) Ετεροκυκλικες ενωσεις, δραστικες ως αναστολεις των βητα-λακταμασων
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacêutico
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
CO6231028A2 (es) Compuestos y composiciones como inhibidores de la proteina quinasa
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
WO2003013484A3 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
AR053301A1 (es) Derivados de pirazina y su uso farmaceutico
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR0312176A (pt) Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario
BR0316895A (pt) Composto, processo para a preparação do composto, composição farmacêutica, novos intermediários, processo para a preparação dos novos intermediários e uso do composto
BR0010139A (pt) Heterociclos bicìclicos substituìdos, processo para seu preparo e seu uso como agentes anti-obesidade e hipocolesterolêmico
BR0312175A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso
NO20090332L (no) 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler
BR0306861A (pt) Combinações que compreendem epotilonas e antimetabólitos
DK1517909T3 (da) Tetracykliske arylcarbonylindoler med serotoninreceptor-affinitet til anvendelse som terpaeutiske midler, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger indeholdende dem
AR040690A1 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar o prevenir la insuficiencia cardiaca
AR027644A1 (es) Compuestos de piridacinil fenil hidrazona, composicion farmaceutica que lo comprende y metodo para el tratamiento de una falla del corazon congestiva quelo emplea
NO20031841L (no) Triazolderivater og farmasöytiske preparater inneholdende disse
NO20025031D0 (no) Benzoksazin- og benzotiazinderivater og anvendelsen derav i medikamenter

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/06/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2777 DE 26/03/2024 POR TER SIDO INDEVIDA.